Chen Jian, Du Fengcai, Hu Baohong, Chi Cheng, Chu Hongjin, Jiang Lixin, Li Peng, Gong Zhaohua
Department of Oncology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. China.
The Central Laboratory, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. China.
Anticancer Res. 2017 Aug;37(8):4557-4561. doi: 10.21873/anticanres.11853.
BACKGROUND/AIM: Bevacizumab combined with standard chemotherapeutics has become a choice of treatment for several kinds of cancers. Hypertension, third-degree albuminuria, thrombosis and cardiotoxicity are the reported side-effects of bevacizumab. Among them, cardiotoxicity is a most severe, but rare outcome. We report a case of a 62-year-old female with colorectal carcinoma who was given bevacizumab-containing chemotherapy for more than 20 months and achieved a stable disease during the entire course of treatment. Thereafter, she developed cardiotoxicity including grade 3 hypertension, tricuspid regurgitation, pulmonary hypertension, left ventricular diastolic dysfunction and pericardial effusion, and was discontinued from the regimen with bevacizumab.
Although clinically-effective, the severe cardiotoxicity of bevacizumab developed after over 20 courses of treatment prompted us to look for optimal chemotherapy prescription in order to achieve a better clinical outcome.
背景/目的：贝伐单抗联合标准化疗药物已成为多种癌症的治疗选择。高血压、三度蛋白尿、血栓形成和心脏毒性是报道的贝伐单抗的副作用。其中，心脏毒性是最严重但罕见的结果。我们报告一例62岁患有结肠直肠癌的女性，接受含贝伐单抗的化疗超过20个月，在整个治疗过程中病情稳定。此后，她出现了心脏毒性，包括3级高血压、三尖瓣反流、肺动脉高压、左心室舒张功能障碍和心包积液，并停用了含贝伐单抗的治疗方案。
尽管贝伐单抗临床有效，但在超过20个疗程的治疗后出现的严重心脏毒性促使我们寻找最佳化疗方案，以获得更好的临床结果。
